According to the Bangkok Post reported on May 14, marijuana cultivators and business owners have decided to gather for a protest, claiming they have suffered significant losses due to a government policy reversal. However, there are also many voices within the medical community and the marijuana industry that support the government's plans. However, groups advocating for marijuana, such as the "Marijuana Future Alliance," demand that if the government intends to reclassify marijuana as a drug, they must provide scientific evidence to support this decision.
Anutin Charnvirakul, an expert and Minister of Interior, stated that the decision to classify marijuana as a drug must be carefully considered, with scientific research and evaluation as a basis. Anutin Charnvirakul is the leader of the Bhumjaithai party, which has previously advocated for the legalization of marijuana.
Deputy Prime Minister Anudin stated, "This issue will not affect the cooperation between the Party of National Trust and the coalition government," and added, "The issue of cannabis should not be politicized.
Although cannabis has been removed from the list of drugs in Thailand since June 2022 and home cultivation is allowed, concerns have been raised in society about issues such as abuse and addiction among adolescents since legalization. Minister of Health Somjate Sapsutin referenced a study from the Chulabhorn Research Institute's Center for Drug Addiction Research, which found that since the legalization of cannabis in 2022, the rate of cannabis use among young people has increased by 10 times.
Even some marijuana growers are in support of canceling the legalization of marijuana, as their income has significantly decreased since marijuana was legalized due to oversupply. Currently, the price of dried marijuana leaves has greatly dropped. However, Thai Prime Minister Chayut Chan-o-cha has issued instructions to the Ministry of Health to revise the regulations that would reclassify marijuana as a controlled substance within the year. It is expected to prohibit recreational use, but allow for medical use under regulation.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
